Treatment Outcome for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma according to Helicobacter pylori Infection Status: A Single-Center Experience
| Autor: | Kwang Jae Lee, Jung Youn Moon, Kwang Duck Ryu, Bong Eun Lee, Seong Oh Park, Geun Am Song, Hye Kyung Jeon, Gwang Ha Kim, Dong Hoon Baek |
|---|---|
| Předmět: |
Adult
Male medicine.medical_specialty Lymphoma medicine.medical_treatment B-cell Antineoplastic Agents Single Center Gastroenterology Helicobacter Infections immune system diseases Stomach Neoplasms Internal medicine hemic and lymphatic diseases Gastroscopy medicine Gastric mucosa Humans Eradication Aged Retrospective Studies Chemotherapy Hepatology biology Helicobacter pylori Radiotherapy business.industry Stomach MALT lymphoma Lymphoma B-Cell Marginal Zone Middle Aged medicine.disease biology.organism_classification bacterial infections and mycoses Radiation therapy medicine.anatomical_structure Treatment Outcome Gastric Mucosa marginal zone Original Article Female business |
| Zdroj: | KoreaMed Gut and Liver |
| Popis: | Background/Aims: Helicobacter pylori eradication therapy has been used as a first-line treatment for H. pylori-positive gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, the management strategy for H. pylori-negative MALT lymphoma remains controversial. Therefore, the aim of this study was to examine the success rate of each treatment option for H. pylori -positive and H. pylori -negative gastric MALT lymphomas. Methods: In total, 57 patients with gastric MALT lymphoma diagnosed between December 2000 and June 2012 were enrolled in the study. The treatment responses were compared between H. pylori-positive and H. pylori-negative gastric MALT lymphomas. Results: Of the 57 patients, 43 (75%) had H. pylori infection. Forty-eight patients received H. pylori eradication as a first-line treatment, and complete remission was achieved in 31 of the 39 patients (80%) with H. pylori-positive MALT lymphoma and in five (56%) of the nine patients with H. pylori-negative MALT lymphoma; no significant difference was observed between the groups (p=0.135). The other treatment modalities, including radiation therapy, chemotherapy, and surgery, were effective irrespective of H. pylori infection status, with no significant difference in the treatment response between H. pylori-positive and H. pylori-negative MALT lymphomas. Conclusions: H. pylori eradication therapy may be considered as a first-line treatment regardless of H. pylori infection status. (Gut Liver 2014;8:408-414) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|